MIGUEL ÁNGEL
CALLEJA HERNÁNDEZ
Forscher in der Zeit 2016-2017
Hospital Universitari de Bellvitge
l'Hospitalet de Llobregat, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital Universitari de Bellvitge (8)
2021
-
Analyzing the clinical benefit of newer therapies for advanced or metastatic non-small-cell lung cancer: application of the ESMO-magnitude of clinical benefit scale v1.1
Acta Oncologica, Vol. 60, Núm. 9, pp. 1225-1232
2018
-
Proposal of the SEOM, SEAP and SEFH for the creation of a National Strategy for Precision Medicine in Cancer
Revista Espanola de Patologia
2017
-
Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer
Mutation Research - Reviews in Mutation Research, Vol. 771, pp. 32-58
-
Interleukins as new prognostic genetic biomarkers in non-small cell lung cancer
Surgical Oncology, Vol. 26, Núm. 3, pp. 278-285
-
Proposal for the Creation of a National Strategy for Precision Medicine in Cancer: A position statement of SEOM, SEAP and SEFH
Farmacia Hospitalaria, Vol. 41, Núm. 6, pp. 688-691
2016
-
Liquid biopsy in early stage lung cancer
Translational Lung Cancer Research, Vol. 5, Núm. 5, pp. 517-524
2015
-
MET/HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer
Pharmacological Research, Vol. 102, pp. 90-106
-
PTEN and PI3K/AKT in non-small-cell lung cancer
Pharmacogenomics, Vol. 16, Núm. 16, pp. 1843-1862